임상화학 분석기 시장 : 제품 유형, 기술, 최종사용자, 지역별(2024-2031년)

Clinical Chemistry Analyzers Market Valuation - 2024-2031

The aging population primarily drives the global market for clinical chemistry analyzers, increased healthcare spending, and the growth of point-of-care testing facilities. According to the analyst from Verified Market Research, the clinical chemistry analyzers market is estimated to reach a valuation of USD 18.22 Billion by 2031 over the forecast subjugating around USD 13.46 Billion valued in 2024.

The demand for early disease detection, improvements in testing efficiency due to technological advancements, and the rising incidence of chronic diseases that necessitate frequent monitoring drive the global market for clinical chemistry analyzers. This enables the market to grow at a CAGR of 4.25% from 2024 to 2031.

Clinical Chemistry Analyzers Market: Definition/ Overview

Clinical chemistry analyzers are automated machines that measure the chemical components of biological fluids such as blood, serum, urine, and cerebrospinal fluid. These analyzers use various techniques, including spectrophotometry, immunoassays, and electrochemistry, to quantify the amounts of molecules such as glucose, electrolytes, enzymes, hormones, and proteins.

Furthermore, clinical chemistry analyzers help healthcare practitioners diagnose, monitor, and manage a wide range of medical diseases, including diabetes, renal disease, liver illnesses, and metabolic irregularities. They are critical in routine health screenings, disease diagnosis, treatment monitoring, and research efforts, giving accurate and fast information that aids clinical decision-making and patient care management.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Key Factors Propelling the Growth of the Market?

The growing prevalence of chronic diseases such as diabetes, cardiovascular ailments, and kidney disease is driving up demand for clinical chemistry analyzers. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide. According to the International Diabetes Federation, the number of adults with diabetes is anticipated to increase from 537 million in 2021 to 783 million by 2045. This rising patient population necessitates frequent monitoring of many biochemical markers, which increases the demand for clinical chemistry analyzers.

The growing older population worldwide is a major driver of the clinical chemistry analyzers market. According to the United Nations Department of Economic and Social Affairs, the number of people over the age of 65 is expected to double from 703 million in 2019 to 1.5 billion by 2050. Older persons frequently require more regular medical testing and monitoring, which has increased the usage of clinical chemistry analyzers for age-related illnesses and chronic disease management.

Furthermore, clinical chemistry analyzers are growing in popularity due to ongoing technical advancements that improve efficiency and accuracy. The American Association for Clinical Chemistry (AACC) reports that the use of automated clinical chemistry analyzers in hospital laboratories has increased by 30% in the last five years. These modern technologies can run numerous tests at the same time, shorten turnaround times, and eliminate human error, making them more appealing to healthcare facilities and boosting market growth.

What Role Do High Initial Costs Play in the Adoption of Clinical Chemistry Analyzers?

Advanced clinical chemistry analyzers, particularly those with cutting-edge technology and automated capabilities, are highly expensive. This high initial investment cost, combined with recurring fees for maintenance, software updates, and reagents, is a considerable barrier for small to medium-sized laboratories and healthcare facilities, particularly in developing nations. This financial barrier hinders the availability and use of modern diagnostic equipment in these regions.

Furthermore, advanced clinical chemistry analyzers require competent individuals to operate, interpret data, and maintain them. The use of very sophisticated analyzers comes with a steep learning curve that requires substantial training. This presents a substantial difficulty in locations with a dearth of competent laboratory technicians or restricted access to ongoing professional development.

Category-Wise Acumens

What Factors Contribute to the Dominance of Reagents in the Market?

According to VMR Analysis, the reagent segment is estimated to hold the largest market share during the forecast period. Unlike analyzers, which are long-lasting capital equipment, reagents are consumables that must be replenished regularly. The need for reagents is ongoing and increases proportionally with the number of tests performed. This ongoing demand assures a consistent revenue stream for manufacturers and distributors, which contributes significantly to the segment's market share. As testing volumes increase due to the increased prevalence of chronic diseases and an aging population, so does the demand for reagents.

The extension of test menus to cover a wider range of biomarkers and specialized tests has resulted in an increase in the variety and complexity of reagents needed. Laboratories are constantly striving to provide more complete testing choices to clinicians and patients, which promotes the demand for specialized reagents. This diversification within the reagents segment can help it gain a bigger market share, as specialist reagents are frequently more expensive.

Furthermore, significant investment has been made in research and development within the reagents market to manufacture high-sensitivity and specificity reagents capable of detecting diseases at an earlier stage or improving result accuracy. These developments not only improve clinical results but also encourage the use of new testing procedures, increasing demand for these novel reagents.

What are the Main Factors Driving Basic Metabolic Panels Segment in the Market?

The basic metabolic panel (BMP) segment is estimated to dominate the clinical chemistry analyzers market during the forecast period. Basic Metabolic Panels are a collection of tests that provide vital information about the body's metabolism, including blood glucose levels, calcium, electrolytes (such as sodium, potassium, and chloride), and kidney function markers (such as BUN and creatinine). Because of their comprehensive breadth, BMPs are commonly utilized in routine medical exams and patient screenings. This extensive use generates a strong demand for BMP testing, which contributes to its considerable market share.

BMPs are vital in emergency rooms and critical care units for quickly assessing a patient's metabolic status and organ performance. In life-threatening situations, quick BMP test findings can guide immediate treatment options for electrolyte imbalances, renal failure, diabetic ketoacidosis, and other conditions. The critical requirement for BMP testing in these circumstances maintains a sustained demand in the market.

Furthermore, the rising global prevalence of chronic diseases such as diabetes, hypertension, cardiovascular disease, and kidney disorders emphasizes the importance of frequent metabolic function monitoring. BMP tests are important in managing these disorders because they provide critical information on blood sugar levels, electrolyte and fluid balance, and renal function. As a result, the global rise in chronic health issues leads to the continued demand for BMP testing.

Country/Region-wise Acumens

What are the Significant Factors Driving the Clinical Chemistry Analyzers Market in Asia Pacific?

According to VMR Analyst, Asia Pacific is estimated to exhibit the highest growth within the clinical chemistry analyzers market during the forecast period. The Asia Pacific region's population is rapidly aging, resulting in a higher frequency of chronic diseases and an increased demand for diagnostic services. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's elder population (aged 65 and more) is predicted to more than double, from 548 million in 2019 to roughly 1.3 billion by 2050. This demographic transition is followed by an increase in chronic diseases, with the World Health Organization estimating that noncommunicable diseases account for 71% of all deaths in the Western Pacific region. The growing older population and chronic illness load are pushing up demand for clinical chemistry analyzers in healthcare facilities throughout the region.

Furthermore, the Asia Pacific region is experiencing an increase in emphasis on preventative healthcare and frequent health check-ups, which is driving demand for diagnostic services. According to a survey by the Asia Pacific Medical Technology Association (APACMed), the preventive health check-up market in India alone is estimated to reach USD 10.7 Billion by 2025, rising at a 27.5% CAGR over 2020. This trend is reflected throughout the region, with Prudential Corporation Asia reporting that 80% of Asians intend to improve their health in the next 24 months. This growing health consciousness is leading to greater use of clinical chemistry analyzers for routine health screenings and early disease diagnosis, which is contributing to the region's strong market growth.

What are the Key Factors Driving the Demand in the North American Region?

North America is estimated to dominate the market during the forecast period. North America has a high prevalence of chronic disorders, which drives the demand for clinical chemistry analyzers. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. According to the CDC, 34.2 million Americans (or 10.5% of the population) had diabetes in 2018. The high frequency of chronic illnesses needs frequent monitoring and testing, increasing demand for clinical chemistry analyzers in the region.

Furthermore, the increased popularity of point-of-care testing in North America is driving demand for compact and portable clinical chemistry analyzers. According to a National Center for Biotechnology Information research, the US point-of-care testing market is predicted to increase at a 6.8% CAGR between 2020 and 2027. According to the American Association for Clinical Chemistry (AACC), the usage of portable clinical chemistry analyzers in North American hospitals and clinics increased by 25% between 2018 and 2022 as a result of the shift toward quick, on-site testing.

Competitive Landscape

The competitive landscape of the clinical chemistry analyzers market is characterized by fierce competition among prominent competitors attempting to extend their market position through tactics such as product innovation, strategic alliances, mergers and acquisitions, and regional expansion.

Some of the prominent players operating in the clinical chemistry analyzers market include:

Roche Diagnostics

Siemens Healthineers AG

Abbott Laboratories

Danaher Corporation

Thermo Fisher Scientific, Inc.

bioMerieux SA

Horiba Ltd.

Mindray Bio-Medical Electronics Co. Ltd

Tosoh Corporation

Hitachi

Shenzhen Mindray Bio-Medical Electronics Co

Alfa Wassermann Diagnostica Ltd

Erba Mannheim

Medica Corporation

Olympus Corporation

Transasia Bio-Medicals Ltd

Latest Developments

In July 2023, Beckman Coulter Diagnostics gained FDA approval for the DxC 500 AU Chemistry Analyzer, an automated device intended for small- to medium-sized laboratories. The analyzer, with its standardized assays, improves clinical decision-making and patient outcomes with proven Six Sigma performance, boosting efficiency and reliability in diagnostic testing.

In December 2022, Abbott introduced the world's smallest implantable and rechargeable spinal cord stimulation system for chronic pain. Eterna SCS uses Abbott's low-dose BurstDR(TM) stimulation, which has the highest level of clinical evidence (1A) and has been shown to relieve pain by 23% more than standard waveform technology.

Clinical Chemistry Analyzers Market, By Category

• Product:
• Analyzers
• Reagents
• Others
• Test Type:
• Basic Metabolic Panels
• Electrolyte Panels
• Liver Panels
• Lipid Profiles
• Renal Panels
• Thyroid Function Panels
• Specialty Chemical Tests
• Others
• Technology:
• Fully-automated
• Semi-automated
• End-User:
• Hospitals and Clinics
• Diagnostic Laboratories
• Research Laboratories & Institutes
• Others
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Analyzers
• 5.3 Reagents
• 5.4 Other Products

6 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY TEST TYPE

• 6.1 Overview
• 6.2 Lipid Profiles
• 6.3 Thyroid Function Panels
• 6.4 Electrolyte Panels
• 6.5 Basic Metabolic Panels
• 6.6 Liver Panels
• 6.7 Renal Panels
• 6.8 Specialty Chemical Tests

7 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY TECHNOLOGY

• 7.1 Overview
• 7.2 Fully-Automated Clinical Chemistry Analyzers Services
• 7.3 Semi-Automated Clinical Chemistry Analyzers Services

8 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY END USER

• 8.1 Overview
• 8.2 Hospitals and Clinics
• 8.3 Diagnostic Laboratories
• 8.4 Research Laboratories & Institutes
• 8.5 Other End Users

9 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL CLINICAL CHEMISTRY ANALYZERS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Diagnostics
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Siemens AG
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Beckman Coulter Inc.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Roche Diagnostics
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 ELITech Group
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Ortho-Clinical Diagnostics
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Thermo Fisher Scientific
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Randox Laboratories Ltd.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Horiba, Ltd.
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Mindray Medical International Limited
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 Appendix

• 13.1 Related Research